Can a simple antibody infusion shield myeloma patients from infections?

NCT ID NCT06976476

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus standard care or standard care alone. The goal is to see if infection rates drop over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IgPro20 (HIZENTRA), a subcutaneous immunoglobulin
What this could lead to: If it works, this could provide a way to reduce serious infections in multiple myeloma patients receiving bispecific antibody therapy, improving their quality of life and treatment tolerance.
What could go wrong: This is a phase 2 trial with only 100 participants, so results may not apply to all patients. The treatment is preventive, not curative, and carries risks like allergic reactions or infusion site issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOGAMMAGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agammaglobulinemia common variable immunodeficiency plasma cell myeloma syndromic agammaglobulinemia infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOGAMMAGLOBULINEMIA HYPOGAMMAGLOBULINEMIA, ACQUIRED MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 10065, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
Mount Sinai Hospital
NOT_YET_RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.